A Leader in Regenerative Medicine
In addition to ACell’s ten 510(k) clearances, we are currently conducting and planning studies and registries to broaden the use of ACell’s device solutions and expand reimbursement for devices currently cleared by the FDA, all with the goal of benefitting a broader range of patients’ needs.
|Diabetic Foot Ulcer||Post-market randomized controlled trial comparing ACell’s wound devices to Dermagraft® for treatment of DFUs that failed to adequately heal following initial standard of care therapy|
|Esophageal Reinforcement||Post-market study using MatriStem® Surgical Matrix for reinforcement of esophageal repair for patients undergoing esophagectomy|
|Pelvic Floor Registry||Post-market study comparing MatriStem Pelvic Floor Matrix to transvaginal native tissue repair for the treatment of pelvic organ prolapse|